196 results about "Human patient" patented technology

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL- 13 in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL- 13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-13 antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL- 13). Also described herein are compositions and combinations comprising an antibody or an antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL- 13, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

A system and method for distinguishing the type of seizures in a human patient, such as an epileptic seizure (ES), or a functional or dissociative seizure (FDS). The system and method use a diagnostic analytical platform that gets heart rate variability (HRV) analytical metrics from a ECG and uses an analytical diagnostic algorithm to determine if an ES or FDS has occurred in the patient. The diagnostic analytical platform can create a model for distinguishing that a predetermined type of seizure has occurred from the HRV analytical metrics.

The present disclosure relates to an apparatus for powering an implant for a human patient and a method for powering an implant for a human patient. Wherein said apparatus comprises an implantable energy source for providing energy to the implant, an energy provider connected to the implantable energy source and connected to an energy consuming part of the implant, the energy provider being configured to store energy to provide a burst of energy to the energy consuming part, wherein the energy provider is configured to be charged by the implantable energy source and to provide the energy consuming part with electrical power during startup of the energy consuming part.

Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient are disclosed herein. In one embodiment, a funnel catheter assembly includes an outer shaft and an inner shaft extending through and coaxial with the outer shaft. An expandable funnel can be coupled to a distal portion of the inner shaft. The funnel catheter assembly further includes a control assembly operably coupled to the proximal portion of the outer shaft and configured to move the outer shaft between a first position and a second position. In the first position, the outer shaft is positioned at least partially over the funnel to constrain the funnel in a compressed state. In the second position, the outer shaft is retracted proximally relative to the funnel such that the funnel can expand to an expanded state.

The disclosure relates to methods of treating multiple sclerosis using Ponesimod. In certain aspects, these include methods of avoiding worsening of fatigue-related symptoms in a human patient who has had no prior disease modifying treatment (DMT) for multiple sclerosis, who has a baseline expanded disability status scale (EDSS) score of ≤3.5, or who does not have Gd+ / T1 lesions at baseline.

Provided are dosages and methods for clinical treatment of human patients using an anti-OX40L antibody, or antigen binding fragment thereof.

Described herein are antibodies, or antigen binding fragments thereof, that bind OX40L and IL-4Rα in combination and methods of use thereof. In certain aspects, described herein are methods of inhibiting OX40L and IL-4Rα biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-OX40L and anti-IL-4Rα antibodies, or antigen binding fragments thereof. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder (e.g., associated with elevated levels of OX40L and / or IL-4). Also described herein are compositions and combinations comprising an antibody or antigen binding region that binds OX40L, an antibody or antigen binding region that binds IL-4Rα, and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Disclosed herein are systems and methods for endovascular treatment of clot material within a blood vessel of a human patient. In one embodiment, a system includes a coring element for coring and separating the clot material. The coring element may include a single structure having a first region, a second region, a third region, and a fourth region. The first region is adjacent to a proximal portion of the unitary structure and includes a first mouth configured to core and separate the clot material. The second region is distal to the first region, is substantially tubular, and includes a first plurality of interconnected struts. The third region is distal to the second region and includes a second mouth configured to core and separate a vascular thrombus. The fourth region is distal to the third region, is substantially tubular, and includes a second plurality of interconnected struts.

A method for assessing a lens capsule stability condition in an eye of a human patient includes simultaneously directing electromagnetic energy in a predetermined spectrum via an energy source onto a pupil of the eye after movement of the eye results in eye saccades occurring therein. The method further includes acquiring images of the eye indicative of the eye saccades using an image capture device and calculating a motion profile of the lens capsule using the images via an ECU. Additionally, the method includes extracting time-normalized lens capsule oscillation trajectories based on the motion profile via the ECU and then model fitting the lens capsule oscillation trajectories via the ECU, thereby assessing the lens capsule instability condition. Also disclosed herein is an automated system for performing an embodiment of the method, the automated system including an energy source, an image capture device, and an ECU.

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The present invention relates to a method for the differential diagnosis of bipolar versus unipolar disorder in a human patient during a depressive phase from a biological sample of the patient, comprising determining the relative proportions of RNA editing variants of at least the A-to-I-edited RNA ZNF267 gene. The present invention also relates to a method for monitoring the treatment of a depressed patient exhibiting bipolar or unipolar disorder. Finally, the present invention provides a kit for the differential diagnosis of bipolar versus unipolar disorder in a patient during a depressive phase.

An acoustic respiratory monitoring system (105) detects, monitors, and / or tracks acoustic features of respiratory conditions for a human patient. Acoustic respiratory data is derived from breathing sound captured by a sensor array (410) comprising a plurality of acoustic sensor elements (412). A plurality of logical channels is determined based on the acoustic respiratory data. An adventitious feature is detected in the breathing sound using the plurality of logical channels, and an indication of an abnormal respiratory sound is provided via a user interface (800), in response to detecting the adventitious feature. The sensor array (410) may be integrated with a wearable article (560), such as a shirt, vest, or belt, for example.

The present invention relates to an anti-GDF15 antibody and to a dosage regimen for the treatment of cancer in a human patient using the anti-GDF15 antibody. The present inventors identified a mechanism by which GDF-15 blocks adhesion and transgression of predominantly T-lymphocytes into tissues. Hence, a novel treatment approach has been established by the present invention that facilitates effector T cell entry into tumor tissue upon blockage of GDF-15 using the antibody of the present invention thereby allowing the treatment of cancer in human patients.

A health status platform includes a receiving component that receives a test result a test of a biological sample collected from a human patient. The test result includes an indication of a presence of an infectious disease in the patient, and an identification and a verification of the patient. The platform includes a certificate component that issues a certificate of origin of the biological sample; and a data merging component that cooperates with a venue access manager that controls access to a venue. The data merging component implements a distributed ledger system that stores encrypted test results of the patient and the identification and verification of the patient, and an end-to-end encryption system that receives an encrypted venue access request from a venue access manager, decrypts the access request, determines if an access request is valid, and if valid, provides an encrypted certificate of origin to the venue access manager.

A method of treating moderate to severe chronic hand eczema in a human patient comprising twice daily administration to the skin of said human patient in need thereof of an acidified aqueous topical composition comprising comprises 20 mg / g delgocitinib on a free base basis or a pharmaceutically acceptable salt.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), an antibody or antigen binding fragment thereof that binds Interleukin-4 Receptor Alpha (IL-4Ra), and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

The invention discloses a construction method of a COL4A5-K229X point mutation X-linked Alport syndrome mouse model. The construction method comprises the following steps: aiming at c.685Agt of a No.12 exon of a mouse COL4A5 gene; carrying out T point mutation, and designing and preparing Cas9 mRNA, gRNA and a donor vector; the components are mixed and then microinjected into fertilized eggs of a C57BL / 6J mouse to obtain an F0-generation mouse; identifying the genotype through PCR (Polymerase Chain Reaction) amplification and Sanger sequencing, and screening positive mice; mating the positive F0-generation mice with the wild-type mice, and breeding F1-generation and subsequent generations; the phenotype of the model is further verified through qPCR, biochemical analysis, light microscopic examination, transmission electron microscope and immunofluorescence. The model constructed by the invention shows hematuria, proteinuria, azemia, podocyte loss and irregular thickening and layering of glomerular basement membrane, is consistent with phenotypes of human XLAS patients, and provides an animal model tool for analyzing pathogenesis and developing treatment strategies.

A method of treating moderate to severe chronic hand eczema in a human patient comprises administering to the skin of the human patient in need thereof an acidified aqueous topical composition comprising 20 mg / g of free base-based digotinib, or a pharmaceutically acceptable salt thereof, twice a day.

To provide a method for segmenting gray matter of the brain of a human patient.SOLUTION: In particular, it relates to a computer-implemented method of segmenting gray matter of a brain of a human patient, the method comprising obtaining a tractogram comprising tractogram streamlines, each tractogram streamline having a first end located in a first portion of the gray matter and a second end located in a second portion of the gray matter. The method also includes using a predetermined clustering algorithm to obtain tractogram streamline clusters, and identifying, for each cluster of at least some of the clusters, a respective first region of gray matter comprising, for each streamline of the cluster, a first end thereof, and a respective second region of gray matter comprising, for each streamline of the cluster, a second end thereof. The method also includes determining a partition based on the identified regions, which includes an iterative merge process that includes merging regions of a region pair based on a metric that represents an amount of overlap.SELECTED DRAWING: Figure 1

The present invention relates to use of biopterin compounds such as 4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin or 4-Amino-(6R,S)-7,8-dihydro-L-biopterin for treating a human patient suffering from a disease condition or disorder that is associated with an increased glutamate level. The invention also relates to the use of such biopterin compounds in a method of treating or preventing glutamate excitotoxicity (glutamate storm) in a patient suffering from a condition that has the potential to result in a pathologically high glutamate level in the brain.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.

Provided herein a method of treating a human patient afflicted with Huntington disease and / or symptoms thereof, by administering to the patient a pharmaceutically effective amount of pridopidine or its pharmaceutically acceptable salt, and optionally at least one analog compound of pridopidine or its pharmaceutically acceptable salt; and low dose anti-dopaminergic medication (ADM).

An apparatus for treating a sexually dysfunctional male patient is provided. The apparatus comprising an implantable vibrator adapted to be implanted within at least one corpus cavernosum of a human patient, wherein said vibrator is adapted to cause vibration in at least one of the corpus cavernosum for stimulating the sexually responsive tissue of the penis.

A cardiac treatment device, including:stimulation circuitry configured to generate a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof improves a condition of heart failure in human patients;atrial arrhythmia detection circuitry; anddecision circuitry which controls the stimulation circuitry to delivery said signal, also when said atrial arrhythmia detection circuitry detects an atrial arrhythmia.

The disclosure provides methods for stratifying human patients with MDD in order to identify a human patient with MDD with insomnia symptoms (MDDIS) where such patients can benefit from treatment with an orexin-2 receptor antagonist, such as seltorexant.

The application provides a catheterization device with an adjusting function, comprising: a catheter, one end of the catheter is provided with a catheter head for guiding urine into the catheter head, and the other end of the catheter is provided with an adjusting switch body for adjusting the rate and on-off of the urine discharged from the other end of the catheter; a balloon, the balloon is arranged on the outer peripheral wall of the catheter close to the catheter head, and the balloon can be filled with a medium to fix the catheter in the bladder of a human patient; two electrodes with opposite polarities, one end of each of the two electrodes penetrates through the catheter and extends into the catheter head along the length direction of the catheter, and the two electrodes are respectively used for connecting the positive electrode and the negative electrode of an electrophysiological monitoring device at the end outside the catheter; wherein the catheter, the catheter head and the balloon are all made of an electrically charged silicone rubber material. The application accelerates the recovery of the self-urination ability of the patient and reduces the risk of urinary tract infection of the patient through the adjustment of the adjusting switch body and the electrodes.

The present invention relates to a combination of antibodies or antigen-binding fragments for use in the treatment of cancer in human subjects requiring such treatment, wherein the combination comprises at least one first antibody or antigen-binding fragment, at least one second antibody or antigen-binding fragment, and at least one third antibody or antigen-binding fragment, each of which antibodies independently and specifically binds to an antigen selected from the group consisting of SLC3A2, CKAP4, Annexin A2, GSTO1, Annexin A5, MX1, RTN4, FASN, and PDIA4. The present invention further relates to a pharmaceutical composition for use in the treatment of cancer in human subjects requiring such treatment, comprising this combination of antibodies or antigen-binding fragments and a pharmaceutically acceptable carrier.

The present disclosure provides compounds of formula (I), as described herein, their pharmaceutically acceptable salts, and their pharmaceutical compositions, which are effective in reducing the expression level of KLF5 or EGR1 in a living cell, and for the treatment of tumors and colorectal cancer in a human patient.

The present invention includes a method of treating fibrosis in a human patient in need thereof comprising administering to the human patient in need of treatment a therapeutically effective amount of Prolactin-Inducible Protein (PIP) which is capable of inhibiting or reversing the formation of pathogenic fibrils, e g., fibrosis that affects at least one organ selected from the group consisting of skin, intestine, heart, liver, lung, and kidney.